We are currently investigating experimental medications for Non-small cell lung cancer (NSCLC)
Non-small cell lung cancer (NSCLC) accounts for about 85–90% of Lung Cancer diagnoses and is composed of 3 subtypes: squamouscell (epidermoid) carcinoma, adenocarcinoma and large cell (undifferentiated) carcinoma.
Answer a few questions below to see if there are clinical trials that might be right for you.
Thank you for Considering a Clinical Trial
Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).
Here are some options for you to find more information:
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
View Trial DetailA Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy
View Trial DetailAn Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
View Trial DetailAn Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
View Trial DetailA Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
View Trial DetailA Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
View Trial DetailA Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
View Trial DetailAn Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
View Trial DetailGet updates on lung cancer clinical trials
Let us help you find a trial you might qualify for
Share your experiences and learn from others.
Visit Our Community
Read the stories below and send us your own.
"I am thankful that I had friends & family to lean on – I don’t like being vulnerable, but being so was freeing in the end." ...
"I am thankful that I had friends & family to lean on – I don’t like being vulnerable, but being so was freeing in the end." ...
View Story
"I noticed a red spot on my shoulder and didn't think too much about it, but after a few more days it didn't change. Nancy recommended that I probably ought to get it checked"
"I noticed a red spot on my shoulder and didn't think too much about it, but after a few more days it didn't change. Nancy recommended that I probably ought to get it checked"
View Story
"They want you to be as safe as possible. So as soon as they notice something is off, they will tell you. And you have the option of saying, 'OK, I'm out.'"
"They want you to be as safe as possible. So as soon as they notice something is off, they will tell you. And you have the option of saying, 'OK, I'm out.'"
View Story
"The medical oncologist did lay out exactly what was going to happen if I did go through this clinical trial, so there weren't any surprises"
"The medical oncologist did lay out exactly what was going to happen if I did go through this clinical trial, so there weren't any surprises"
View StoryLung cancer has been the most common cancer in the world for several decades, and despite advancements in treatment, has resulted in more deaths than any other cancer.
Learn More
Bristol-Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol-Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement.
